<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03049657</url>
  </required_header>
  <id_info>
    <org_study_id>ANGIOLITE</org_study_id>
    <nct_id>NCT03049657</nct_id>
  </id_info>
  <brief_title>Efficacy of Angiolite Stent vs a Second-generation Drug-eluting Stent Xience for Percutaneous Coronary Intervention</brief_title>
  <official_title>Randomized Clinical Trial to Compare the Efficacy of Angiolite Stent Versus a Second-generation Drug-eluting Stent Such as Xience in Patients With Indication of Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiva2 S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiva2 S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial with an &quot;European Community marked&quot; medical device in patients with ischemic
      heart disease and clinical indication of coronary revascularization with drug-eluting stent.

      Clinical follow-up will be done according to this way: first month telephone or face-to-face
      interview and at 6 ± 1 month an Angiography follow up + OCT (optical coherence tomography)

      A randomized clinical trial to compare the efficacy of Angiolite Stent versus a
      second-generation drug-eluting stent such as Xience stent.(non-inferiority design)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2016</start_date>
  <completion_date type="Actual">January 28, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy:Measure the late loss (LL) in the follow-up of the Angiolite stent is not different from the late loss of the xience stent (non-inferiority)</measure>
    <time_frame>6 months</time_frame>
    <description>Measure the late loss (LL) in the follow-up of the Angiolite stent is not different from the late loss of the xience stent (non-inferiority)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety:Compare TLF rate (cardiovascular death, target vessel-related myocardial infarction (MI) with definite thrombosis or ischemia-driven Target Lesion Revascularization (TLR))</measure>
    <time_frame>1 year</time_frame>
    <description>Compare TLF rate (cardiovascular death, target vessel-related myocardial infarction (MI) with definite thrombosis or ischemia-driven Target Lesion Revascularization (TLR)) during follow-up for no differences between Angiolite and Xience stents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follow up</measure>
    <time_frame>1 year</time_frame>
    <description>Compare differences between Angiolite and Xience stent during the follow-up in independent components of the major adverse cardiac events rate: All cause death, any myocardial infarction and any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis rate</measure>
    <time_frame>1 year</time_frame>
    <description>Discard differences in definite and probable thrombosis rate (according to Academic Research Consortium criteria) between both stents Angiolite and Xience</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE (Major Adverse Cardiac Events)</measure>
    <time_frame>1 year</time_frame>
    <description>- Compare the differences between the rate of MACE (all-cause death, any myocardial infarction and any revascularization) of Angiolite and Xience during follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Drug-eluting Stent</condition>
  <arm_group>
    <arm_group_label>ANGIOLITE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angiolite</intervention_name>
    <description>Percutaneous coronary intervention</description>
    <arm_group_label>ANGIOLITE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience</intervention_name>
    <description>Percutaneous coronary intervention</description>
    <arm_group_label>Xience</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical or subclinical ischemic heart disease with indication of
             percutaneous revascularization.

          -  &quot;De Novo&quot; lesions ≥ 70%

          -  Reference diameters ≥ 2 mm and ≤ 4 mm Accepted participation in the registration with
             the signing of informed consent

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Pregnancy

          -  Intolerance or allergy to anti platelet or anticoagulant therapy

          -  Elective surgical procedure scheduled within 6 months after inclusion in the study

          -  Expectancy of life of less than 1 year.

          -  Impossibility of doing 1 year clinical follow-up.

          -  Primary angioplasty in patients with killip class III-IV or mechanical complications.

          -  Patient with pre-procedure restenosis.

          -  Patients who will not be treated all lesions with the Angiolite stent.

          -  Total occlusions

          -  Truncus disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Ibares</last_name>
    <role>Study Director</role>
    <affiliation>Cardiva2 S.L.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>Leon</city>
        <state>León</state>
        <zip>24001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Valle de Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramón Jiménez</name>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

